Le Lézard
Classified in: Health
Subjects: POL, AVO

AMCP Praises the House E&C Subcommittee on Health for Advancing H.R. 2026 'Pharmaceutical Information Exchange (PIE) Act of 2017'


WASHINGTON, Jan. 17, 2018 /PRNewswire-USNewswire/ -- The Academy of Managed Care Pharmacy (AMCP) applauds the U.S. House Energy and Commerce Committee's Subcommittee on Health for its approval today of H.R. 2026, the "Pharmaceutical Information Exchange (PIE) Act of 2017." The bill now goes to the full Energy and Commerce Committee for consideration.

Academy of Managed Care Pharmacy. (PRNewsFoto/Academy of Managed Care Pharmacy)

H.R. 2026, sponsored by Rep. Brett Guthrie (R-KY2), would allow manufacturers to proactively share certain clinical and economic information with decision makers on emerging therapies in advance of Food and Drug Administration approval, an area currently restricted by federal law and FDA regulation.

"The Academy is very pleased with today's approval of H.R. 2026," said AMCP CEO Susan A. Cantrell, RPh, CAE. "We thank bill sponsor Rep. Brett Guthrie (R-KY2) for his leadership on this important issue. The thrust of the PIE Act is to give health plans the economic and scientific information they need to make coverage determinations more quickly on medications in the pipeline ? so that upon FDA approval patients can get access to innovative therapies sooner. For patients waiting for breakthrough medicines, every minute counts."

Cantrell also notes the bill contains requirements that communications be "truthful, nonmisleading, and based on competent and reliable scientific evidence." This, along with safeguards that communications take place only between sophisticated parties such as health plans and formulary committees, ensures that such exchanges will be responsible, she added.

"The PIE Act will allow AMCP's 8,000 members ? who manage pharmacy benefits for more than 270 million Americans ? to more accurately forecast and make coverage decisions sooner on these emerging products. AMCP is proud to have led on this issue on behalf of our members," Cantrell said.

AMCP in fall 2017 led a multi-stakeholder effort to develop recommendations on allowing pre-approval information exchange. H.R. 2026 closely aligns with these recommendations. For more information on AMCP's recommendations allowing pre-approval information exchange, read "Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval."

About AMCP
The Academy of Managed Care Pharmacy (AMCP) is the nation's leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy's 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government. www.amcp.org

SOURCE Academy of Managed Care Pharmacy


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: